Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment

  • Authors:
    • Mitsuyuki Suzuki
    • Toru Ishikawa
    • Ai Sakuma
    • Satoshi Abe
    • Hiroko Abe
    • Fujiko Koyama
    • Tomomi Nakano
    • Aya Ueki
    • Hirohito Noguchi
    • Erina Hasegawa
    • Shiori Yamagata
    • Miki Kobayashi
    • Kazutaka Ohashi
    • Hiroshi Hirosawa
    • Takako Fukazawa
    • Yuka Maruyama
    • Toshiaki Yoshida
  • View Affiliations

  • Published online on: October 5, 2016     https://doi.org/10.3892/etm.2016.3785
  • Pages: 3353-3358
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The rate of sustained virologic response (SVR) has increased in patients with chronic hepatitis C (CHC; genotype 1) since triple treatment with pegylated interferon (PEG‑IFN), ribavirin (RBV) and telaprevir (TVR) was included in Japanese health insurance. However, side effects such as high‑grade anemia and skin disorders means it is important to investigate the extent to which quality of life (QOL) is maintained during treatment. The impact on health‑related (HR) QOL, as a result of TVR‑based triple treatment was investigated long‑term (48 weeks) in 34 patients (18 men, 16 women) following TVR‑based triple treatment, using the 36‑item short form health survey (SF‑36). While scores for physical health were significantly lower during treatment, an improvement was seen in patients who showed complete response to treatment from 12 weeks following treatment (P<0.05). HRQOL improved significantly following completion of TVR‑based triple treatment in these complete‑responders, with higher scores compared with those prior to treatment. Anemia and skin symptoms appeared frequently during treatment and scores for physical health dropped. Particular care needs to be taken in regards to the management of side effects during TVR treatment. Further evaluations using the SF‑36 may help in controlling doses to achieve SVR.
View Figures
View References

Related Articles

Journal Cover

November-2016
Volume 12 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Suzuki M, Ishikawa T, Sakuma A, Abe S, Abe H, Koyama F, Nakano T, Ueki A, Noguchi H, Hasegawa E, Hasegawa E, et al: Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment. Exp Ther Med 12: 3353-3358, 2016.
APA
Suzuki, M., Ishikawa, T., Sakuma, A., Abe, S., Abe, H., Koyama, F. ... Yoshida, T. (2016). Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment. Experimental and Therapeutic Medicine, 12, 3353-3358. https://doi.org/10.3892/etm.2016.3785
MLA
Suzuki, M., Ishikawa, T., Sakuma, A., Abe, S., Abe, H., Koyama, F., Nakano, T., Ueki, A., Noguchi, H., Hasegawa, E., Yamagata, S., Kobayashi, M., Ohashi, K., Hirosawa, H., Fukazawa, T., Maruyama, Y., Yoshida, T."Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment". Experimental and Therapeutic Medicine 12.5 (2016): 3353-3358.
Chicago
Suzuki, M., Ishikawa, T., Sakuma, A., Abe, S., Abe, H., Koyama, F., Nakano, T., Ueki, A., Noguchi, H., Hasegawa, E., Yamagata, S., Kobayashi, M., Ohashi, K., Hirosawa, H., Fukazawa, T., Maruyama, Y., Yoshida, T."Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment". Experimental and Therapeutic Medicine 12, no. 5 (2016): 3353-3358. https://doi.org/10.3892/etm.2016.3785